Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Intestinal Neoplasms 1EGFR-mutant Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ductal 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Docetaxel 4pembrolizumab 3Pemetrexed 3Nivolumab 2Cisplatin 2Carboplatin 2tislelizumab 1rofecoxib 1paclitaxel poliglumex 1osimertinib 1nazartinib 1lenvatinib 1cemiplimab 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Radiosurgery 1RO5126766 1Platinum Compounds 1Midazolam 1Gemcitabine 1Gefitinib 1Food 1Esomeprazole 1Drug Therapy 1Dabigatran 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer × nazartinib × Thoracic × Clear all
NCT02108964 2024-12-11

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Novartis

Phase 1/2 Completed
225 enrolled 31 charts
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡